


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|---|
| (51) International Patent Classification ⁵ : C12N 15/85 | | A1 | (11) International Publication Number: WO 94/28150 (43) International Publication Date: 8 December 1994 (08.12.94) |
| (21) International Application Number: PCT/CA94/00283 (22) International Filing Date: 18 May 1994 (18.05.94) | | (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| (30) Priority Data: 08/066,397 21 May 1993 (21.05.93) US | | Published With international search report. | |
| (71) Applicant: MCGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street West, Montreal, Quebec H3A 2T5 (CA). | | | |
| (72) Inventors: MADER, Sylvie; Apartment 1009, 4870 Cote des Neiges, Montreal, Quebec H3V 1H3 (CA). WHITE, John, H.; Apartment 1009, 4870 Cote des Neiges, Montreal, Quebec H3V 1H3 (CA). | | | |
| (74) Agents: CONN, David, L. et al.; Smart & Biggar, P.O. Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA). | | | |

(54) Title: EXPRESSION VECTORS RESPONSIVE TO STEROID HORMONES



(57) Abstract

Expression vector adapted for expression of cloned genes in an animal cell comprising a steroid responsive promoter, the promoter consisting essentially of a plurality of glucocorticoid response elements (GREs), a TATA box, and an initiator element containing a transcriptional initiator site located from 20 to 50 bases from the TATA box, the promoter lacking upstream elements which bind nuclear factor I, and the vector further comprising a restriction endonuclease site downstream from the promoter for insertion of DNA to be expressed from the promoter, wherein the DNA is expressed from the vector in an animal cell.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

DESCRIPTIONExpression Vectors Responsive to Steroid HormonesBackground of the Invention

This invention relates to vectors suitable for expression of a desired protein in an animal cell in response to the presence of one or more steroid hormones.

Transcription of eukaryotic class II genes is regulated by a complex array of trans-acting transcription factors which bind to specific DNA sequences in the promoter of a target gene. On most promoters transcriptional preinitiation complexes are assembled at the TATA box which is generally located 25-30 base pairs (bp) 5' to the site of initiation (Buratowski et al., 56 Cell 549, 1989). Preinitiation complex assembly is regulated, in part, by factors which bind to DNA sequences known as enhancers most often situated at varying distances upstream of the TATA box/initiation site (Mitchel and Tjian, 245 Science 371, 1989; Ptashne and Gann, 346 Nature 329, 1990; and Lewin, 61 Cell 1161, 1990). Enhancers can be located immediately adjacent to the site of transcriptional initiation or several kilobases distant from it (Zenke et al., 5 EMBO J. 387, 1986; and Jantzen et al., 49 Cell 29, 1987). The activity of enhancer factors can be directly responsive to specific intercellular signals or indirectly via intracellular transduction pathways (Green and Chambon, 4 Trends in Genet. 309, 1988; Evans, 240 Science 889, 1988; Wahli and Martinez, 5 FASEB J. 2243, 1991; Gronemeyer, 25 Ann. Rev. Genet. 89, 1991; Montiminy et al., 13 Trends in Neurolog. Sciences 184, 1990; Angel and Karin, 1072 Biochim. Biophys. Acta. 129, 1991; Lin et al., 70 Cell 777, 1991; Bauerle, 1072 Biochim. Biophys. Acta. 63, 1991; and Hunter and Karin, 70 Cell 375, 1992).

The nuclear receptors represent a family of transcriptional enhancer factors which act by binding to

specific DNA sequences found in target promoters known as response elements (REs) (Green and Chambon, *supra*; Evans, *supra*; Wahli and Martinez, *supra*; and Gronemeyer, *supra*). Specific members of the nuclear receptor family represent 5 the primary intracellular targets for small lipid soluble ligands such as steroid and thyroid hormones, retinoids and vitamin D₃, and as such act as ligand-inducible transcription factors. Sequence comparisons (Krust et al., 5 EMBO J. 891, 1986) and structure-function analyses 10 (Giguere et al., 46 Cell 645, 1986; Kumar et al., 51 Cell 941, 1987; Kumar and Chambon, 55 Cell 145, 1988; and Green and Chambon, 325 Nature 75, 1987) have shown that the receptors are composed of a series of conserved domains. The most highly conserved domain is the DNA binding domain 15 located in region C (Krust et al., *supra*; Green and Chambon *supra*; and Evans and Hollenberg, 52 Cell 1, 1988) containing a 66-68 amino acid core composed of two zinc fingers (Schwabe et al., 348 Nature 458, 1990; Hard et al., 249 Science 157, 1990; and Luisi et al., 352 Nature 20 497, 1991) which is essential for recognition of REs. Three amino acids adjacent to the N-terminal zinc finger of the DNA binding domain, known as the P-box, are critical for DNA sequence recognition (Mader et al., 338 Nature 271, 1989; Umesomo and Evans, 57 Cell 1139, 1989; 25 and Danielson et al., 57 Cell 1131, 1989). A subfamily composed of the glucocorticoid, mineralocorticoid, progesterone and androgen receptors contain Gly, Ser and Val at discriminatory positions of the P-box and recognize AGAACCA half-sites arranged in a palindrome with a 3 bp 30 spacer region (Mader et al., *supra*; Umesomo and Evans, *supra*; and Danielson et al., *supra*). The ligand binding domain, located C-terminal to the DNA binding domain in region E, is less well conserved among the receptors and contains a ligand-inducible transcriptional activation 35 function (Green and Chambon, *supra*; Evans, *supra*; Wahli and Martinez, *supra*; Gronemeyer, *supra*; Giguere et al., 46 Cell 645, 1986; and Kumar et al., 51 Cell 941, 1987).

Transcriptional activating domains have also been identified in the poorly conserved N-terminal A/B regions of the glucocorticoid and estrogen receptors (Giguere et al., *supra*; Kumar et al., *supra*; and Tora et al., 59 Cell 447, 1989).

Response elements are often found in multiple arrays, usually located upstream of the site of transcriptional initiation (Jantzen et al., *supra*; Martinez et al., 6 EMBO J. 3719, 1987; and Burch et al., 8 Mol. Cell. Biol. 1123, 10 1988). Functional analysis of two glucocorticoid response elements (GREs) located far upstream of the rat tyrosine aminotransferase (TAT) gene has shown that they combine synergistically to mediate transcriptional activation by the glucocorticoid receptor (GR) (Jantzen et al., *supra*). 15 The two nonconsensus estrogen response elements (EREs) of the Xenopus vitellogenin B1 gene are virtually inactive in isolation, but together mediate estrogen-dependent transcriptional activation in transiently transfected cells (Martinez et al., *supra*). The degree of synergism between 20 paired EREs or GREs is dependent on their sequence, the spacing between them and their distance from the TATA box of the promoter (Ponglikitmongkol et al., 9 EMBO J. 2221, 1990; and Schule et al., 332 Nature 87, 1988). Several studies have also shown that nuclear receptors and other 25 classes of transcriptional regulators can combine to activate transcription synergistically (Tora et al., *supra*; and Schule et al., *supra*).

Promoters activated by specific inducible nuclear receptors are well suited for eukaryotic expression 30 vectors since expression of genes can be regulated simply by controlling the concentration of ligand present in growth media (Kumar *supra*; Lee et al., 294 Nature 259, 1984; Ucker et al., 27 Cell 257, 1981; and Metzger et al., 334 Nature 31, 1988). Glucocorticoid-inducible promoters 35 such as that of the long terminal repeat of the mouse mammary tumor virus (MMTV) have been widely used in this regard because the GR is expressed in a wide variety of

mammalian cell types. The MMTV GRE is composed largely of a series of half-sites (Payvar et al., 35 Cell 381, 1983; and Scheidereit et al., 304 Nature 749, 1983). While the MMTV promoter can be induced by ligand-bound receptors for both glucocorticoids and progesterone when introduced into cells by transient transfection, it is selectively responsive to glucocorticoids when propagated on an episomal vector (Hager and Archer, in "Nuclear Hormone Receptors: Molecular Mechanisms, Cellular functions and Clinical Abnormalities," (Parker, M.G. ed.), Academic Press Ltd. 217, 1991). It is proposed that the nucleosome structure of the episomal DNA selectively inhibits access of the progesterone receptor to the response element.

Schena et al., 88 Proc. Natl. Acad. Sci. USA 10421, 1991, describe a steroid inducible expression system for plant cells in which six 26-base pair GREs are fused upstream of a plant site of transcription initiation with a plant TATA box as the sole promoter element. By providing glucocorticoid receptor and glucocorticoid hormone, inducible expression of a gene in a plant cell was achieved.

Summary of the Invention

Applicant has constructed a mammalian expression vector containing a synthetic promoter composed of several high affinity glucocorticoid response elements placed upstream of a minimal promoter TATA region. In transiently transfected HeLa cells in the presence of dexamethasone, one of these promoters was at least 50-fold more efficient than the mouse mammary tumor virus long terminal repeat in expressing bacterial chloramphenicol acetyl-transferase (CAT) activity. When the vector was introduced stably into the HeLa cell genome CAT activity was induced from 10 to more than 50-fold by dexamethasone in 6 of 8 responsive clones. The levels of both basal and induced expression varied from one clone to the next, probably due to an effect of chromosomal location on

promoter activity. When propagated stably in HeLa cells in an Epstein-Barr virus episomal vector, the promoter was greater than 50-fold inducible, and its activity was strictly dependent on the presence of dexamethasone. The 5 promoter when stably propagated in HeLa cells was inducible by progesterone in the presence of a transiently transfected progesterone receptor expression vector. These promoters are widely applicable for the strictly controlled high level expression of target genes in 10 eukaryotic cells that contain either the glucocorticoid or progesterone receptors.

Thus, in the first aspect, the invention features an expression vector adapted to replicate in animal cells (*i.e.*, having the requisite animal origin of replication), 15 which includes a plurality of glucocorticoid responsive elements (GREs) and a minimal promoter. Applicant has discovered that the use of such a minimal promoter with such GREs provides a promoter responsive not only to glucocorticoid but also to other receptors including 20 progesterone, androgen, and mineralocorticoid receptors when that vector is stably integrated within a host cell.

By "minimal promoter" is simply meant a promoter that consists, essentially, of a plurality of the glucocorticoid responsive elements, a TATA box, and an initiator 25 element containing a transcriptional initiation site (Smale and Baltimore, 57 Cell 103, 1989) which is of mammalian or viral origin) located about 20 to 50 bases from the TATA box. No other upstream elements are provided, for example, those which bind nuclear factor I or 30 other such upstream element factors. The vector further includes a restriction endonuclease site downstream from the promoter for insertion of DNA to be expressed from that promoter. Such a promoter is of viral or mammalian origin.

35 By "glucocorticoid responsive element" is meant an element having at least one-half consensus sequence, where that consensus sequence is 5' AGAACANNNTGTTCT 3', (where

N is any nucleotide base), or any equivalent sequence which is able to bind the above receptors for glucocorticoids, progesterones, androgen, or mineralocorticoid. Such GREs may be synthetically prepared or may be 5 isolated from naturally occurring GREs. Thus, the GRE is simply a family of related DNA sequences which are recognized by one or more of the above receptors. Those in the art will recognize that such GREs can be readily synthesized or discovered using standard binding assays 10 for detection of DNA elements able to bind the above receptors. (Schmid et al., 8 EMBO Journal 2257, 1989.)

By "TATA box" is simply meant a DNA binding site of mammalian or viral origin for the TATA box binding protein referred to as TFIID, which is the first protein found in 15 transcriptional preinitiation complex assembly. Such a box, generally, has the nucleotide base sequence TATA (hence its name) which may be followed by another TATA sequence or by AAA. Those of ordinary skill in the art will recognize other variants of this sequence. All that 20 is necessary in the invention is that the TATA box be able to bind the TFIID protein such that transcriptional initiation can occur. As noted, this box is generally placed between 20 and 50 bases from a transcriptional initiation site, which is the point at which transcription 25 will occur. Such sites are well known in the art.

In preferred embodiments, the TATA box is positioned 25 to 30 bases from the initiation site; the GREs are placed upstream from the TATA box; and at least two GREs are placed within 100 bases of this TATA box. In a more 30 preferred embodiment, at least 5 GREs are provided within the vector, all located within about 500 bases of the TATA box. Preferably the GREs are positioned between 20 and 60 bases apart, most preferably between 30 and 40 bases apart. In the most preferred embodiment, the expression 35 vector includes a promoter which is responsive to not only glucocorticoid receptors but also progesterone, androgen,

and mineralocorticoid receptors, when the vector is stably integrated within a genome.

In a related aspect, the invention features a method for expressing a desired protein in response to one or 5 more of a glucocorticoid, progesterone, androgen, and mineralocorticoid, by providing a suitable DNA sequence encoding the desired protein within an expression vector described above, and providing that vector within a suitable expression system such as a mammalian cell, 10 either in an integrated or nonintegrated fashion.

The advantages of the presently described vectors include the following. Since the vector includes a minimal promoter composed of only a TATA box, an initiator element and multiple GREs, and (unlike the MMTV promoter) 15 lacks binding sites for other regulatory transcription factors, its activity is easily controlled solely by regulating the concentration of steroid hormone in the growth media. In addition, since the promoter is exclusively regulated by the activity of hormone bound 20 steroid receptors there is no detectable activity when the promoter is propagated under controlled conditions in the absence of steroid. This is particularly important when one wants controlled expression of a gene whose product is lethal to the cell when expressed constitutively. Unlike 25 MMTV, the promoter maintains responsiveness to progesterone as well as glucocorticoids when stably propagated in cells, and the promoter is more highly inducible by glucocorticoids than MMTV.

Other features and advantages of the invention will 30 be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

The drawing will first briefly be described.

Drawing

The Figure is a representation of pGRE5 expression vectors of this invention.

The following methods were used to prepare vectors 5 of this invention. This exemplifies the invention but is not limiting to the invention. Those in the art can readily construct equivalent vectors within the pending claims using similar or equivalent techniques.

Vectors

10 Previous studies with estrogen-inducible minimal promoters have shown that a TATA region and one or more estrogen response elements are sufficient for a transcriptional response to estrogen in the presence of ligand-bound estrogen receptor (Ponglikitmongkol et al., 15 *supra*). In HeLa cells, promoters based on the Ad2MLP TATA region (-34 to +33) have undetectable basal activity in the absence of inducer (Ponglikitmongkol et al., *supra*), and are therefore potentially useful in inducible expression vectors. Here, we constructed a series of 20 glucocorticoid-responsive minimal promoters composed of the Ad2MLP TATA region and one or more GREs from the rat TATA gene (Jantzen et al., *supra*) placed upstream of a rabbit β -globin reporter gene in the plasmid pAL10 (Ponglikitmongkol et al., *supra*).

25 Specifically, a 35 bp oligonucleotide containing the rat TAT GRE flanked by *Bam*HI and *Bgl*II ends was concatemerized in the presence of *Bam*HI, *Bgl*II and T4 DNA ligase and bands corresponding to dimers and pentamers were purified from a 5% polyacrylamide gel for insertion 30 into the *Bgl*II site (-65) of pAL10 (Ponglikitmongkol et al., *supra*). Recombinants containing a single GRE, or head-to-tail direct repeats of GREs conserving the *Bgl*II site a -65 were isolated to create GRE/pAL10, GRE2/pAL10 and GRE5/pAL10. GRE5/pAL10 was then modified to remove 35 unnecessary sequence and restriction sites, and a polylinker containing sites for EcoRI, KpnI, SmaI, SacI,

XhoI, HindIII, and BglII was inserted in either orientation to create GRE5-1 and pGRE5-2 (see Fig.).

The rabbit β -globin sequence of pGRE5 runs from the naturally occurring BamHI site to the EcoRI site and 5 contains the second globin intron (Breathnach and Harris, 11 Nucleic Acids Research 7119, 1983). To create GRE5/CAT recombinants, the BglII-SmaI fragment from pBLCAT8+ (Klein-Hitpass et al., 46 Cell 1053, 1986), containing the CAT gene was excised and inserted in the pGRE5-1 or 10 pGRE5-2 polylinker digested with SmaI and BglII in the sense and antisense orientations, respectively. The pGRE1tkCAT and pGRE2tkCAT plasmids were created by inserting one or two perfectly palindromic GREs upstream 15 of the Herpes Simplex virus thymidine kinase promoter in pBLCAT8+. To create p220.2-GRE5/CAT recombinants, the XbaI-SalI fragment (see Fig.) from the pGRE5/CAT was inserted in the Epstein-Barr virus episomal vector p220.2 (Yates et al., 313 Nature 812, 1985; and Hambor et al., 85 Proc. Natl. Acad. Sci. USA 4010, 1988), digested with XbaI 20 and XhoI.

Induction of Expression

Standard techniques were used to test for dexamethasone-inducible transcription, recombinants were transiently transfected in HeLa cells along with pG1B 25 which constitutively expresses the rabbit β -globin gene (Ponglikitmongkol et al., *supra*) and acts as an internal control, and transcription was monitored by quantitative S1 nuclease analysis.

Specifically, for transient transfections, 5 μ g of 30 CAT expression vector or 2 μ g of pAL10 derivatives, 1 μ g of pG1B internal control plasmid (Kumar et al., *supra*), for quantitative S1 nuclease analysis or 3 μ g of β -galactosidase expression vector pCH220 for CAT assays, and 35 11-13 μ g of BlueScribe (Stratagene) carrier DNA were transfected onto 9 cm plates of HeLa cells in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum

at approximately 50% confluency using the calcium phosphate co-precipitation technique (Banerji et al., Cell 299, 1981). Dexamethasone (25nM) was added immediately after transfection and at 24 hours post-transfection. 5 Cells were harvested 44-48 hours after transfection. For stable transfections, HeLa cells were transected with 15 µg of pGRE5/CAT, 1 µg of neomycin resistance gene expression vector pRc-RSV (Invitrogen) and 4 µg of BlueScribe carrier DNA. G418 (1mg/ml) was added starting 10 48 hours after transfection and G418-resistant colonies were picked 3-4 weeks later.

To test for dexamethasone-inducible CAT activity, cells from G418-resistant clones were split into duplicate 9 cm plates and treated as indicated with 25 nM 15 dexamethasone for 48 hours prior to harvesting. Alternatively, HeLa cells were transfected with 15 µg of the Epstein-Barr virus episomal vector p220.2-GRE5/CAT and 5 µg of BlueScribe carrier DNA. Hygromycin (250 µg/ml) was added 48 hours later for selection.

20 Induction of CAT activity of the G418-resistant HeLa cell line 19-11 (any equivalent cell line can be used) by progesterone was tested by transfecting cells with 1 µg of human progesterone expression vector hPRO (Kastner et al., 265 J. Biol. Chem. 12163, 1990), 3 µg of pCH110 and 16 µg 25 or BlueScribe carrier.

Cells were harvested for CAT assays in 250 µl of 0.25 M Tris-HCl (pH7.5) (Webster et al., 54 Cell 199, 1988). CAT assays were performed as described by Tora et al., *supra*. Quantities of extracts derived from transiently 30 transfected cells were normalized for β-galactosidase activity. Quantitative S1 nuclease analysis was performed as described by Ponglikitmongkol et al., *supra*.

Quantitative S1 nuclease analysis showed that no transcription was observed from the Ad2MLP recombinant 35 lacking GRE sequences either in the absence or presence of dexamethasone, or from any of the GRE-containing recombinants tested in the absence of hormone. The

recombinant GRE1 containing a single GRE upstream of the Ad2MLP TATA region did not produce detectable transcription in the presence of dexamethasone. In contrast, dexamethasone-inducible transcription was observed from the Ad2MLP in recombinants containing two or more GREs. Promoters containing five GREs were 8-fold more inducible than those containing only two elements. The promoter of the GRE5 recombinant was also greater than 3-fold more efficient in the presence of dexamethasone than the constitutively active promoter of an Ad2MLP recombinant containing a equivalently positioned SV40 enhancer.

The above results show that introduction of several GREs upstream of the Ad2MLP TATA region creates a promoter which has very low basal activity and is highly inducible in HeLa cells by the endogenous levels of ligand-activated GR. We therefore constructed the two eukaryotic expression vectors based on this promoter, pGRE5-1 and pGRE5-2, containing polylinker sequences in opposite orientations (see Fig.). The polylinker of each vector was inserted between a fragment of rabbit β -globin gene sequence which contains an intron, and a sequence from the SV40 genome containing a polyA addition signal. To test the capacity of these vectors to induce expression of high levels of protein we inserted the bacterial chloramphenicol acetyl-transferase (CAT) gene into pGRE5-2 as described above, and introduced the recombinant plasmid into HeLa cells by transient transfection.

Inducible expression of CAT activity by pGRE5-2/CAT was compared to other dexamethasone-inducible CAT expression vectors containing synthetic promoters and to MMTV/CAT, using quantities of extract normalized to the activity of the β -galactosidase internal control.

No induction of CAT activity by dexamethasone was observed in extract of cells transfected with pBLCAT8+ which contains the Herpes Simplex virus thymidine kinase (tk) promoter but no GREs. Insertion of one or two GREs

upstream of the tk promoter gave rise to dexamethasone-inducible CAT activity. The induced activity of the GRE2tk promoter was 3-fold higher than that observed with the GRE1tk promoter. Strikingly, transfection of either 5 of two independent preparations of GRE5-2/CAT into HeLa cells in the presence of dexamethasone gave rise to more than 10- and 30-fold more CAT activity than observed with GRE2tkCAT and GRE1tkCAT, respectively. No induction of activity was observed when the CAT gene was inserted in 10 pGRE5-1 in the antisense orientation.

Virtually no dexamethasone-inducible CAT activity was observed in extracts of cells transfected with MMTV/CAT. However, activity was clearly observed if 25-fold more extract was used. Under these conditions, the activity of 15 pGRE5-2/CAT in the presence of dexamethasone is at least 50-fold higher than that of the MMTV/CAT. Moreover, whereas the inducible activity of the MMTV promoter was enhanced more than 5-fold by co-transfection of a glucocorticoid receptor expression vector, the activity of 20 the GRE5 promoter was not significantly affected, indicating that the GRE5 promoter is efficiently inducible by endogenous levels of GR in HeLa cells.

We also compared the activity in HeLa cells of pGRE5-2/CAT to the constitutively active SV40 and cytomegalovirus (CMV) enhancer-based promoters of pSV2-CAT and CMV-CAT 25 and saw that, in the presence of dexamethasone, the pGRE5 promoter was more efficient than either the pSV2 or pCMV promoters. Under these conditions the CMV promoter was as efficient as the induced MMTV promoter. These results 30 demonstrate that high levels of induction by dexamethasone can be obtained when using a promoter composed solely of multiple GREs and a TATA region.

Since the pGRE5 vectors contain a synthetic promoter it is important to verify that they are functional when 35 stably propagated in cells. The pGRE5/CAT plasmid was therefore introduced into HeLa cells by co-transfection with the pRcRSV vector which expresses the neomycin

resistance gene. CAT assays of G418-resistant clones expressing dexamethasone-dependent CAT activity were performed. The CAT gene was inserted in pGRE5-1 in the antisense or sense orientation.

5 Of 22 neomycin-resistant clones, 8 expressed CAT activity. These 8 clones displayed variable levels of background activity and dexamethasone inducibility. The quantities of extract tested correspond to 1/250th (1 μ l) and 1/25th (10 μ l) of total extract from 9 cm plates of
10 cells harvested at 70% confluence (\sim 2.5 μ g and \sim 25 μ g of protein, respectively). Six clones, 17-4, 18-5, 18-7, 18-8, 19-11 and 20-5, showed a combination of little background activity and high levels of induction in the presence of dexamethasone. Indeed, no CAT activity was
15 visible with extracts of the clone 19-11 not treated with dexamethasone under these conditions.

The GRE5 promoter is strongly inducible by dexamethasone when propagated in the Epstein-Barr virus episomal vector p220.2 (Yates et al., *supra*; and Hambor et al.,
20 *supra*). Dexamethasone-dependent CAT activity of two independent clones of hygromycin-resistant HeLa cells carrying the GRE5/CAT expression cassette in the Epstein-Barr virus expression vector p2202 was measured. No CAT activity was observed in extracts of cells transfected
25 with p220.2-GRE51-/CAT which carries the CAT gene in the antisense orientation. In contrast, very low background activity and high dexamethasone-inducibility were observed in extracts of cells transfected with p220.2-GRE5-2/CAT which expresses the CAT gene. These results are typical
30 of other clones tested. The levels of activity observed in clones 6 and 7 are comparable to that observed with G418-resistant HeLa clone 19-11.

Induction of the GRE5 promoter by progesterone was also measured. The TAT GRE can confer responsiveness to
35 both glucocorticoids and progesterone in transiently transfected cells when placed upstream of an unresponsive promoter (Tsai et al., 55 Cell 361, 1988), and the

progesterone receptor binds to the element *in vitro* (Tsai et al., *supra*). We used the HeLa cell line 19-11, which contains GRE5/CAT, to determine if the GRE5 promoter is progesterone responsive in stably transfected cells. HeLa
5 19-11 cells were treated with 100 nM progesterone for 48 hours prior to harvesting. No CAT activity was observed in 19-11 cells treated or not the progesterone. However, upon transient transfection with the human progesterone receptor expression vector hPR0, progesterone-responsive
10 CAT activity was observed. These results demonstrate that the GRE5 promoter is progesterone responsive in the presence of the progesterone receptor when stably integrated in the HeLa cell genome.

In summary, we have developed a fully defined,
15 synthetic steroid-inducible promoter/expression system that is applicable for the tightly controlled expression of cloned genes in wide variety of cell types expressing glucocorticoid or progesterone receptors, and in cells expressing androgen or mineralocorticoid receptors.

20 Other embodiments are within the following claims.

Claims

1. Expression vector adapted for replication in an animal cell comprising a glucocorticoid responsive promoter, said promoter consisting essentially of a plurality of glucocorticoid response elements (GREs), a viral or mammalian TATA box, and a viral or mammalian initiator element with a transcriptional initiator site located from 20 to 50 bases from said TATA box, said promoter lacking upstream elements which bind nuclear factor I, and said vector further comprising a restriction endonuclease site downstream from said promoter for insertion of DNA to be expressed from said promoter; wherein said DNA is expressed from said vector in an animal cell.

15 2. The vector of claim 1, wherein said TATA is from 25 to 30 bases from said initiation site.

3. The vector of claim 1, wherein said GREs are upstream from said TATA box.

4. The vector of claim 1, wherein at least two said 20 GREs are within 100 bases of said TATA box.

5. The vector of claim 1, wherein at least five said GREs are within 500 bases of said TATA box.

6. The vector of claim 5, wherein said GREs are from 20 to 500 bases apart.

25 7. The vector of claim 5, wherein said GREs are from 30 to 40 bases apart.

8. The vector of claim 1, wherein said GRE comprises at least one half consensus sequence of a GRE able to bind a glucocorticoid, progesterone, androgen or 30 mineralocorticoid receptor.

9. The vector of claim 8, wherein said GREs comprises a consensus sequence for a said GRE able to bind a glucocorticoid, progesterone, androgen or mineralocorticoid receptor.


5 10. Promoter consisting essentially of a plurality of glucocorticoid response elements (GREs), a TATA box, and an initiator site containing a transcriptional initiator site located from 20 to 50 bases from said TATA box, said promoter lacking upstream elements which bind 10 nuclear factor I, and said vector further comprising a restriction endonuclease site downstream from said promoter for insertion of DNA to be expressed from said promoter, wherein said promoter is responsive to ligand-bound glucocorticoid, progesterone, androgen or 15 mineralocorticoid receptor when transiently transfected into cells, when stably integrated within a genome, or when stably propagated in an episomal vector.

11. Method for expression of a desired protein in an animal cell, comprising the steps of:

- 20 (a) providing an expression vector adapted for gene expression in an animal cell, comprising a glucocorticoid responsive promoter said, promoter consisting essentially of a plurality of glucocorticoid response elements (GREs), a TATA box, and a 25 transcriptional initiation site located from 20 to 50 bases from said TATA box, said promoter lacking upstream elements which bind nuclear factor I, and said vector further comprising a restriction endonuclease site downstream from said promoter for insertion of DNA to be 30 expressed from said promoter;
- (b) cutting said expression vector at said restriction endonuclease site;
- (c) inserting DNA encoding said desired protein in said site;
- (d) ligating the inserted DNA; and

(e) introducing said vector into an expression cell under expression inducing conditions, either by transient transfection, by stable integration into the chromosome, or by propagation in an autonomously 5 replicating episomal vector.

1 / 1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 94/00283

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | <p>NUCL. ACIDS RES. vol. 17, no. 12 , 26 June 1989 , IRL PRESS, OXFORD, ENGLAND; pages 4589 - 4604</p> <p>D.I. ISRAEL AND R.J. KAUFMAN 'High inducible expression from vectors containing multiple GRE's in CHO cells overexpressing the glucocorticoid receptor'</p> <p>see page 4589, line 6 - line 9 see page 4590, line 19 - line 21 see page 4591, line 4 - line 28 see page 4597, line 7 - line 37</p> <p>---</p> <p style="text-align: center;">-/--</p> | 1-11 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *& document member of the same patent family

2

Date of the actual completion of the international search

22 August 1994

Date of mailing of the international search report

05-09-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Inte... nal Application No

PCT/CA 94/00283

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | <p>EMBO JOURNAL vol. 7, no. 11, November 1988, IRL PRESS LIM., OXFORD, ENGL.; pages 3389 - 3395 U. STRÄHLE ET AL. 'Synergistic action of the glucocorticoid receptor with transcription factors' see page 3391, left column, line 25 - page 3391, right column, line 2; figure 1B ---</p> | 1-11 |
| Y | <p>NUCL. ACIDS RES. vol. 20, no. 11, 11 June 1992, IRL PRESS, OXFORD, ENGLAND; pages 2755 - 2760 J. FILMUS ET AL. 'Synergistic induction of promoters containing metal- and glucocorticoid-responsive elements' see page 2757, left column, line 10 - page 2759, right column, line 18 ---</p> | 1-11 |
| Y | <p>MOL. CELL. BIOL. vol. 6, no. 12, December 1986, AM. SOC. MICROBIOL., WASHINGTON, D.C. US; pages 4526 - 4538 M.G. TOOHEY ET AL. 'Multiple hormone-inducible enhancers as mediators of differential transcription' see page 4530, right column, line 5 - page 4533, right column, line 46 ---</p> | 1-11 |
| Y | <p>EP,A,0 299 303 (BOEHRINGER MANNHEIM GMBH) 18 January 1989 see page 2, line 1 - page 3, line 56; claims 1-6; figure 1 ---</p> | 1-11 |
| Y | <p>EMBO JOURNAL vol. 9, no. 7, July 1990, IRL PRESS LIM., OXFORD, ENGL.; pages 2221 - 2231 M. PONGLIKITMONGKOL ET AL. 'Synergistic activation of transcription by the human estrogen receptor bound to tandem responsive elements' cited in the application see page 2228, right column, paragraph 2 - page 2230, left column, line 54; figure 1 ---</p> | 1-11 |
| 2 | | |

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/CA 94/00283

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A | <p>CELL vol. 49, no. 1 , 10 April 1987 , CELL PRESS, CAMBRIDGE, MA,US; pages 29 - 38 H.-M. JANTZEN ET AL. 'Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene' cited in the application the whole document ---</p> | 1-11 |
| P,X | <p>WO,A,93 20218 (CONNAUGHT LABORATORIES LIMITED) 14 October 1993 see page 3, line 27 - line 30 see page 4, line 12 - line 21; figure 1 ---</p> | 1-11 |
| P,X | <p>PROC. NATL. ACAD SCI. vol. 90, no. 12 , 15 June 1993 , NATL. ACAD SCI., WASHINGTON, DC, US; pages 5603 - 5607 S. MADER AND J.H. WHITE 'A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells' see page 5603, left column, line 1 - page 5607, left column, line 40 -----</p> | 1-11 |

INTERNATIONAL SEARCH REPORT

Int. Application No.

Information on patent family members

PCT/CA 94/00283

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|---|--|
| EP-A-0299303 | 18-01-89 | DE-A- 3723075 DE-A- 3878760, JP-A- 1037293 US-A- 4983518 | 19-01-89 08-04-93 07-02-89 08-01-91 |
| WO-A-9320218 | 14-10-93 | AU-B- 3883393 | 08-11-93 |